The therapeutic potential of vasopressin receptor antagonists in congestive heart failure

Bibliography

• GHEORGHIADE M, GATTIS WA, O'CONNER C et al.: Effects of tolvaptan vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA (2004) 291(16):1963–1971.
   Google Scholar
• ••The ACTIV in CHF study is the firstrandomised trial to evaluate both the acute and chronic effects of the V2 antagonist tolvaptan in patients hospitalised with CHF.
   Google Scholar
• SCHRIER RW, ABRAHAM W: Hormones and hemodynamics in heart failure. N Engl. Med. (1999) 341:577–585.
   PubMed Web of Science ®Google Scholar
• HEART FAILURE SOCIETY OF AMERICA: HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. Card. Fad. (1999) 5:357–382.
   PubMed Web of Science ®Google Scholar
• CUFFE MS, CALIFF RM, ADAMS KF Jr et al.: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA (2002) 287:1541–1547.
   Google Scholar
• SAN GHI P, URETSKY BE SCHWARZ ER: Vasopressin antagonism: a future treatment option in heart failure. Eur. Heart J. (2005) 26(6):538–543.
   PubMed Web of Science ®Google Scholar
• ••This recent paper provides a comprehensive review of the potential role for vasopressin antagonists as therapeutic agents in patients with CHE
   Google Scholar
• LEE CR, WATKINS M, PATTERSON JH et al.: Vasopressin: a new target for the treatment of heart failure. Am. Heart J. (2003) 146:9–18.
   PubMed Web of Science ®Google Scholar
• ••This article summarises the relevant dataof the AVP antagonists for the treatment of heart failure, and reviews the role of AVP in both normal physiology and the pathogenesis of heart failure.
   Google Scholar
• SZATALOVITZ VL, ARNOLD PE, CHAIMOVITZ C et al: Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl. I Med. (1981) 305:263–266.
   PubMed Web of Science ®Google Scholar
• RIEGGER GAJ: Vasopressin and renin in high output heart failure of rats: hemodynamic effects of elevated plasma hormone levels. Cardiovasc. Pharmacol (1985) 7:1–8.
   PubMed Web of Science ®Google Scholar
• FRANCIS GS, BENEDICT C, JOHNSTONE DE et al.: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 82:1724–1729.
   PubMed Web of Science ®Google Scholar
• ROULEAU JL, PACKER M, MOYE L et al.: Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J. Am. Coll. Cardiol (1994) 24:583–591.
   PubMed Web of Science ®Google Scholar
• ROBERTSON GL, SHELTON RL, ATHAR S et al: The osmoregulation of vasopressin. Kidney In] (1976) 10:25–37.
   PubMed Web of Science ®Google Scholar
• URETSKY BE VERBALIS JG, GENERALOVICH T et al.: Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. Am. Physiol (1985) 248:H396–H401.
   Web of Science ®Google Scholar
• GOLDSMITH SR, FRANCIS GS, COWLEY AW et al: Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J. Am. Coll. Cardiol (1986) 8:779–783.
   PubMed Web of Science ®Google Scholar
• TAHARA A, TOMURA Y, WADA K et al.:Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc. Res. (1998) 38:198–205.
   PubMed Web of Science ®Google Scholar
• NAKAMURA Y, HANEDA T, OSAKI J et al.: Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V la receptor. Eur. Pharmacol. (2000) 391:39–48.
   PubMed Web of Science ®Google Scholar
• FUKUZAWA J, HANEDA T, KIKUCKI Ket al: Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mal. Cell. Biochem. (1999) 195:93–98.
   PubMed Web of Science ®Google Scholar
• NICOD P, WAEBER B, BUSSIEN JP et al.: Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am..! Cardiol (1985) 55:1043–1047.
   PubMed Web of Science ®Google Scholar
• YAMAMURA Y, OGAWA H, CHIHARA T et al: OPC-21268, an orally effective, non peptide vasopressin V1 receptor antagonist. Science (1991) 252:572–574.
   PubMed Web of Science ®Google Scholar
• YAMAMURA Y, NAKAMURA S, ITOH S et al.: OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacologic profile and aquaretic effect by single and multiple oral dosing in rats. Pharmacol Exp. Ther. (1998) 287:860–867.
   PubMed Web of Science ®Google Scholar
• HIRANO T, YOSHITAKA Y, NAKAMURA S et al: Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J. Pharmacol Exp. Ther. (2000) 292:288–294.
   PubMed Web of Science ®Google Scholar
• GHEOGHIADE M, NIAZI I, OUYANG J et al: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure. Circulation (2003) 107:2690–2696.
   PubMed Web of Science ®Google Scholar
• •In this earlier study in patients with CHF taking furosemide, tolvaptan was associated with a reduction in body weight compared with placebo, as well as increases In urine volumes and reductions in urine osmolality and sodium concentrations.
   Google Scholar
• RUSSELL SD, SELARU P, PYNE DA et al: Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am. Heart J. (2003) 145:179–186.
   PubMed Web of Science ®Google Scholar